N/A
N=163
Impact of Pharmacotherapy Management in Patients With Alzheimer's Disease
Alzheimer's Disease
Bottom Line
View on ClinicalTrials.gov: NCT02222181 ↗Enrolled (actual)
163
Serious AEs
0.0%
Results posted
May 2016
Primary outcome: Primary: Mini-mental State Examination (MMEE) — 12; 12 score — p=0.23
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Pharmacotherapy Management (Other)
- Age
- Adult, Older Adult · 60+ yrs
- Sex
- All
- Sponsor
- Universidade Estadual Paulista Júlio de Mesquita Filho
- Primary completion
- Feb 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mini-mental State Examination (MMEE) |
12; 12 | 0.23 |
| PRIMARY Clinical Dementia Rating (CDR) |
1.6; 1.7 | 0.05 |
| SECONDARY Systolic Blood Pressure |
136.6; 126.7 | 0.03 sig |
| SECONDARY Total Cholesterol |
202.2; 187.6 | <0.001 sig |
| SECONDARY Triglycerides |
154.1; 137.8 | 0.025 sig |
| SECONDARY Glycemia |
121.9; 93.9 | <0.001 sig |
| SECONDARY Diastolic Blood Pressure |
75.49; 73.03 | 0.05 |
Summary
In Brazil, patients with Alzheimer's disease (AD) receiving free drugs of government. Even having access to, little is known about the effectiveness, safety and adherence of drug therapy in this group of patients. The research aims to promote adherence and develop strategies to address Drug-Related Problems (DRP's) in AD patients elderly of reference centre for the Elderly of Araraquara. The clinical parameters will be assessed at the beginning and after the educational intervention period from April 2014 to April 2015.
Eligibility Criteria
Inclusion Criteria
- Elderly patients who are assisted in CRIA, diagnosed with Alzheimer's in use of rivastigmine or donepezil or galantamine, assisted by the "Program for special drugs".
- Be resident in the city of Araraquara / SP
- Accept part of pharmacotherapeutic follow-up;
- Sign the Statement of Informed Consent Form (ICF).
Exclusion Criteria
- Fold over pharmacotherapy follow-up;
- Being institutionalized;
- Patients unable to respond to collection instruments MMSE and CDR data;
- Patient without phone contact.
Data sourced from ClinicalTrials.gov (NCT02222181). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.